CD200 checkpoint inhibitor (University of Minnesota/OX2 Therapeutics)

N/A

Report date: 2025/01/26 16:42:58

Base Information

Drug NameCD200 checkpoint inhibitor (University of Minnesota/OX2 Therapeutics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionCell surface glycoprotein CD200 receptor 1 blockers
TargetsCell surface glycoprotein CD200 receptor 1
Therapy Area/IndicationsBrain NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Minnesota
China Registration ClassN/A

Develop Information

Active CompaniesOX2 Therapeutics
Inactive CompaniesUniversity Of Minnesota
Active IndicationsBrain NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A